Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

Reprogramming neuroblastoma by diet-enhanced polyamine depletion.

Nature·2025
Same author

Reprogramming neuroblastoma by diet-enhanced polyamine depletion.

bioRxiv : the preprint server for biology·2024
Same author

The Role of α-Linolenic Acid and Its Oxylipins in Human Cardiovascular Diseases.

International journal of molecular sciences·2023
Same author

Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency.

Nature metabolism·2023
Same journal

Obesity-driven extracellular vesicle signaling in cancer: mechanistic insights and clinical implications.

Oncogenesis·2026
Same journal

Integrated scRNA-Seq and functional profiling reveal CD52 as a driver of pancreatic ductal adenocarcinoma metastasis and immunosuppression.

Oncogenesis·2026
Same journal

Metabolic plasticity and therapeutic opportunity in cancer.

Oncogenesis·2026
Same journal

Editorial Expression of Concern: Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.

Oncogenesis·2026
Same journal

Extracellular matrix stiffness determines the phenotypic behavior of dedifferentiated melanoma cells through a DDR1/2-dependent YAP mechanotransduction pathway.

Oncogenesis·2026
Same journal

Testican-1 activates Wnt/β-Catenin signaling to drive colorectal cancer progression.

Oncogenesis·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.4K

Reprogramming lipid metabolism in pediatric cancers.

Vinzent L Lindemann1,2, Nazek Noureddine1,2, Raphael J Morscher3,4

  • 1Pediatric Cancer Metabolism Laboratory, Children's Research Center, University of Zurich, Zurich, Switzerland.

Oncogenesis
|April 30, 2026
PubMed
Summary
This summary is machine-generated.

Pediatric cancers reprogram lipid metabolism for growth. Targeting these metabolic pathways shows promise but requires further research into patient-specific dependencies for clinical success.

More Related Videos

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

6.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Related Experiment Videos

Last Updated: May 2, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.4K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

6.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Area of Science:

  • Oncology
  • Metabolic Biochemistry
  • Cancer Biology

Background:

  • Metabolic reprogramming is crucial for cancer development and growth.
  • Pediatric cancers utilize aberrant transcriptional networks to alter lipid metabolism.
  • This rewiring involves activating biosynthetic pathways, membrane remodeling, and metabolic flexibility.

Purpose of the Study:

  • To review recent advances in understanding lipid metabolism reprogramming in pediatric cancers.
  • To examine key areas including transcriptional drivers, lipid catabolism, ferroptosis evasion, and tissue-specific adaptations.
  • To discuss the clinical translation of targeting lipid metabolism in pediatric oncology.

Main Methods:

  • Literature review synthesizing recent advances in pediatric cancer lipid metabolism.
  • Analysis of transcriptional drivers of fatty acid and cholesterol synthesis.
  • Examination of lipid catabolism roles in metabolic stress.
  • Investigation of ferroptosis evasion mechanisms and metastatic adaptations.

Main Results:

  • Transcriptional drivers activate fatty acid and cholesterol synthesis in pediatric cancers.
  • Lipid catabolism supports energy, acetyl-CoA, and NADPH under stress.
  • Cancer cells evade ferroptosis via desaturation and membrane remodeling.
  • Metabolic adaptations facilitate metastasis to bone marrow and cerebrospinal fluid.

Conclusions:

  • Preclinical studies identify vulnerabilities (e.g., FASN, SCD, HMGCR) but clinical impact is unproven.
  • Challenges exist in translating lipid metabolism therapies to the clinic.
  • Future success depends on understanding lipid flux and patient-specific dependencies.